Nebivolol: a review of its use in the management of hypertension and chronic heart failure

• Published in: Drugs (New York, N.Y.) Vol. 66; no. 10; pp. 1389 - 1409
• Main Authors: Moen, Marit D, Wagstaff, Antona J
• Format: Journal Article
• Language: English
• Published: New Zealand Wolters Kluwer Health, Inc 01.01.2006
• Subjects: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists - pharmacology; Adrenergic beta-Antagonists - therapeutic use; Antihypertensive Agents - pharmacology; Antihypertensive Agents - therapeutic use; Benzopyrans - pharmacology; Benzopyrans - therapeutic use; Chronic Disease; Ethanolamines - pharmacology; Ethanolamines - therapeutic use; Heart Failure - drug therapy; Humans; Hypertension - drug therapy; Nebivolol; Vasodilator Agents - pharmacology; Vasodilator Agents - therapeutic use
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/00003495-200666100-00007

Nebivolol is a third-generation beta-adrenoceptor antagonist. It differs from other beta-adrenoceptor antagonists as it combines highly selective beta(1)-adrenoceptor antagonist properties with nitric oxide-mediated vasodilatory actions and beneficial effects on endothelial function. Nebivolol is approved in Europe and several other countries for the treatment of essential hypertension and in Europe for the treatment of stable mild or moderate chronic heart failure (CHF) in addition to standard therapies in elderly patients aged >or=70 years. Nebivolol is an effective antihypertensive agent and is well tolerated in patients with hypertension. The drug also effectively decreased the composite endpoint of mortality and cardiovascular hospital admission in elderly patients with CHF and was generally well tolerated in this population. Nebivolol should be considered as an alternative first-line treatment option for patients with uncomplicated mild to moderate essential hypertension and in elderly patients with CHF.